Erschienen in:
01.12.2006 | ORIGINAL CONTRIBUTIONS
Long-acting medications for the hyperkinetic disorders
A systematic review and European treatment guideline
verfasst von:
Priv. Doz. Dr. Tobias Banaschewski, David Coghill, Paramala Santosh, Alessandro Zuddas, Philip Asherson, Jan Buitelaar, Marina Danckaerts, Manfred Döpfner, Stephen V. Faraone, Aribert Rothenberger, Joseph Sergeant, Hans-Christoph Steinhausen, Edmund J.S. Sonuga-Barke, Eric Taylor
Erschienen in:
European Child & Adolescent Psychiatry
|
Ausgabe 8/2006
Einloggen, um Zugang zu erhalten
Abstract
A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.